Viracta Therapeutics to Present at the Jefferies Virtual Healthcare Conference


SAN DIEGO, May 27, 2021 /PRNewswire/ -- Viracta Therapeutics, Inc. (Viracta or the Company), a precision oncology company targeting virus-associated malignancies, today announced that Company management will present at the Jefferies Virtual Healthcare Conference taking place June 1-4, 2021. The Company will also participate in one-on-one investor meetings at the conference.

Details on the presentation can be found below.


Thursday, June 3, 2021


2:30 PM ET


Corporate presentation


A replay of the presentation will be available on the "Events and Webcasts" section of the Viracta website at

About Viracta Therapeutics, Inc.
Viracta is a precision oncology company targeting virus-associated malignancies. Viracta's proprietary investigational drug, nanatinostat, is currently being evaluated in combination with the antiviral agent valganciclovir as an oral combination therapy in a Phase 2 clinical trial for EBV-positive lymphoma. Viracta is pursuing application of this inducible synthetic lethality approach in other EBV-associated malignancies, such as nasopharyngeal carcinoma, gastric carcinoma, and other virus-related cancers.

For additional information please visit

Investor Relations Contact:                    

Company Contact:

Joyce Allaire                       

Dan Chevallard

LifeSci Advisors                                                  

Chief Operating Officer and Chief Financial Officer                

(212) 915-2569                                        

(858) 771-4193


Viracta Therapeutics, Inc. Logo (PRNewsfoto/Viracta Therapeutics, Inc.)



Cision View original content to download multimedia:

SOURCE Viracta Therapeutics, Inc.


Back to news